RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CRVS
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Corvus Pharmaceuticals
(Updated on Jul 03, 2024)

Sell candidate since Jun 17, 2024 Loss -7.77% PDF

No changes to the price of Corvus Pharmaceuticals stock on the last trading day (Wednesday, 3rd Jul 2024). During the last trading day the stock fluctuated 2.82% from a day low at $1.77 to a day high of $1.82. The price has risen in 5 of the last 10 days but is still down by -4.81% for this period.

Given the current short-term trend, the stock is expected to rise 24.74% during the next 3 months and, with a 90% probability hold a price between $2.22 and $3.17 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CRVS Signals & Forecast

There are few to no technical positive signals at the moment. The Corvus Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.81 and $2.04. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, May 17, 2024, and so far it has fallen -22.27%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Corvus Pharmaceuticals stock

Corvus Pharmaceuticals finds support from accumulated volume at $1.73 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0500 between high and low, or 2.82%. For the last week the stock has had daily average volatility of 6.25%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CRVS) For The Upcoming Trading Day Of Friday 5th

For the upcoming trading day on Friday, 5th we expect Corvus Pharmaceuticals to open at $1.79, and during the day (based on 14 day Average True Range), to move between $1.64 and $1.92, which gives a possible trading interval of +/-$0.143 (+/-8.06%) up or down from last closing price. If Corvus Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 16.12% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.73 (2.81%) than the resistance at $1.91 (7.30%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Corvus Pharmaceuticals stock A Buy?

The Corvus Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Corvus Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -4.090 Sell Candidate Unchanged

Predicted Opening Price for Corvus Pharmaceuticals of Friday, July 5, 2024

Fair opening price July 5, 2024 Current price
$1.79 ( 0.562%) $1.78

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CRVS

Fibonacci Support & Resistance Levels

Level Price
R3 1.84 3.37%
R2 1.82 2.30%
R1 1.81 1.63%
Price 1.78
S1 1.77 -0.511%
S2 1.76 -1.17%
S3 1.74 -2.25%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.03 14.04%
R2 1.96 10.11%
R1 1.91 7.30%
Price 1.78
S1 1.73 -2.81%
S2 1.68 -5.62%
S3 1.51 -15.17%

FAQ

What is the symbol for Corvus Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Corvus Pharmaceuticals is CRVS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Corvus Pharmaceuticals Stock?
The Corvus Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Corvus Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Corvus Pharmaceuticals Stock?
Corvus Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Corvus Pharmaceuticals Stock.

What's the current price of Corvus Pharmaceuticals Stock?
As of the end of day on the Jul 03, 2024, the price of an Corvus Pharmaceuticals (CRVS) share was $1.78.

What is the 52-week high and low for Corvus Pharmaceuticals Stock?
The 52-week high for Corvus Pharmaceuticals Stock is $3.16 and the 52-week low is $1.05.

What is the market capitalization of Corvus Pharmaceuticals Stock?
As of the Jul 03, 2024, the market capitalization of Corvus Pharmaceuticals is 111.341M.

When is the next earnings date for Corvus Pharmaceuticals?
The upcoming earnings date for Corvus Pharmaceuticals is Aug 13, 2024.
Click to get the best stock tips daily for free!

About Corvus Pharmaceuticals

Corvus Pharmaceuticals Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa... CRVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT